|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mo L, Pospichalova V, Huang Z, Murphy SK,
Payne S, Wang F, Kennedy M, Cianciolo GJ, Bryja V, Pizzo SV and
Bachelder RE: Ascites increases expression/function of multidrug
resistance proteins in ovarian cancer cells. PLoS One.
10:e01315792015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khrunin AV, Khokhrin DV, Moisseev AA,
Gorbunova VA and Limborska SA: Pharmacogenomic assessment of
cisplatin-based chemotherapy outcomes in ovarian cancer.
Pharmacogenomics. 15:329–337. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li J, Jiang K, Qiu X, Li M, Hao Q, Wei L,
Zhang W, Chen B and Xin X: Overexpression of CXCR4 is significantly
associated with cisplatin-based chemotherapy resistance and can be
a prognostic factor in epithelial ovarian cancer. BMB Rep.
47:33–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khrunin A, Ivanova F, Moisseev A, Khokhrin
D, Sleptsova Y, Gorbunova V and Limborska S: Pharmacogenomics of
cisplatin-based chemotherapy in ovarian cancer patients of
different ethnic origins. Pharmacogenomics. 13:171–178. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu S, Fu GB, Tao Z, OuYang J, Kong F,
Jiang BH, Wan X and Chen K: MiR-497 decreases cisplatin resistance
in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget.
6:26457–26471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Spizzo R, Almeida MI, Colombatti A and
Calin GA: Long non-coding RNAs and cancer: A new frontier of
translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang J, Ahmad A and Sarkar FH: The role of
MicroRNAs in breast cancer migration, invasion and metastasis. Int
J Mol Sci. 13:13414–13437. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takahashi K, Yan IK, Kogure T, Haga H and
Patel T: Extracellular vesicle-mediated transfer of long non-coding
RNA ROR modulates chemosensitivity in human hepatocellular cancer.
FEBS Open Bio. 4:458–467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F
and Liu Y: Long non-coding RNA UCA1 increases chemoresistance of
bladder cancer cells by regulating Wnt signaling. FEBS J.
281:1750–1758. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brun JL, Feyler A, Chêne G, Saurel J, Brun
G and Hocké C: Long-term results and prognostic factor in patients
with epithelial ovarian cancer. Gynecol Oncol. 78:21–27. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen J, Fu Z, Ji C, Gu P, Xu P, Yu N, Kan
Y, Wu X, Shen R and Shen Y: Systematic gene microarray analysis of
the lncRNA expression profiles in human uterine cervix carcinoma.
Biomed Pharmacother. 72:83–90. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lv M, Xu P, Wu Y, Huang L, Li W, Lv S, Wu
X, Zeng X, Shen R, Jia X, et al: LncRNAs as new biomarkers to
differentiate triple negative breast cancer from non-triple
negative breast cancer. Oncotarget. 7:13047–13059. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, Sun S, Pu JK, Tsang AC, Lee D,
Man VO, Lui WM, Wong ST and Leung GK: Long non-coding RNA
expression profiles predict clinical phenotypes in glioma.
Neurobiol Dis. 48:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Spurlock CF III, Tossberg JT, Guo Y,
Collier SP, Crooke PS III and Aune TM: Expression and functions of
long noncoding RNAs during human T helper cell differentiation. Nat
Commun. 6:69322015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Odening KE, Li W, Rutz R, Laufs S,
Fruehauf S, Fishelson Z and Kirschfink M: Enhanced complement
resistance in drug-selected P-glycoprotein expressing
multi-drug-resistant ovarian carcinoma cells. Clin Exp Immunol.
155:239–248. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
O'Connor R, O'Leary M, Ballot J, Collins
CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A,
Kennedy S, et al: A phase I clinical and pharmacokinetic study of
the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in
combination with epirubicin in patients with advanced cancer.
Cancer Chemother Pharmacol. 59:79–87. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Obata H, Yahata T, Quan J, Sekine M and
Tanaka K: Association between single nucleotide polymorphisms of
drug resistance-associated genes and response to chemotherapy in
advanced ovarian cancer. Anticancer Res. 26:2227–2232.
2006.PubMed/NCBI
|
|
22
|
Scartozzi M, De Nictolis M, Galizia E,
Carassai P, Bianchi F, Berardi R, Gesuita R, Piga A, Cellerino R
and Porfiri E: Loss of hMLH1 expression correlates with improved
survival in stage III–IV ovarian cancer patients. Eur J Cancer.
39:1144–1149. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Muenyi CS, States VA, Masters JH, Fan TW,
Helm CW and States JC: Sodium arsenite and hyperthermia modulate
cisplatin-DNA damage responses and enhance platinum accumulation in
murine metastatic ovarian cancer xenograft after hyperthermic
intraperitoneal chemotherapy (HIPEC). J Ovarian Res. 4:92011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Metzinger DS, Taylor DD and Gercel-Taylor
C: Induction of p53 and drug resistance following treatment with
cisplatin or paclitaxel in ovarian cancer cell lines. Cancer Lett.
236:302–308. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Raspollini MR, Amunni G, Villanucci A,
Castiglione F, Rossi Degl'Innocenti D, Baroni G, Paglierani M and
Taddei GL: HER-2/neu and bcl-2 in ovarian carcinoma:
Clinicopathologic, immunhistochemical and molecular study in
patients with shorter and longer survival. Appl Immunohistochem Mol
Morphol. 14:181–186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dao MD, Alwan LM, Gray HJ, Tamimi HK, Goff
BA and Liao JB: Recurrence patterns after extended treatment with
bevacizumab for ovarian, fallopian tube, and primary peritoneal
cancers. Gynecol Oncol. 130:295–299. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dhillon S: Bevacizumab combination
therapy: A review of its use in patients with epithelial ovarian,
fallopian tube, or primary peritoneal cancer. BioDrugs. 27:375–392.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen YA and Aravin AA: Non-coding RNAs in
transcriptional regulation: The review for current molecular
biology reports. Curr Mol Biol Rep. 1:10–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rinn JL and Chang HY: Genome regulation by
long noncoding RNAs. Annu Rev Biochem. 81:145–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Latos PA, Pauler FM, Koerner MV, Şenergin
HB, Hudson QJ, Stocsits RR, Allhoff W, Stricker SH, Klement RM,
Warczok KE, et al: Airn transcriptional overlap, but not its lncRNA
products, induces imprinted Igf2r silencing. Science.
338:1469–1472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li H, Yu B, Li J, Su L, Yan M, Zhu Z and
Liu B: Overexpression of lncRNA H19 enhances carcinogenesis and
metastasis of gastric cancer. Oncotarget. 5:2318–2329. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jin G, Sun J, Isaacs SD, Wiley KE, Kim ST,
Chu LW, Zhang Z, Zhao H, Zheng SL, Isaacs WB and Xu J: Human
polymorphisms at long non-coding RNAs (lncRNAs) and association
with prostate cancer risk. Carcinogenesis. 32:1655–1659. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Arase M, Horiguchi K, Ehata S, Morikawa M,
Tsutsumi S, Aburatani H, Miyazono K and Koinuma D: Transforming
growth factor-β-induced lncRNA-Smad7 inhibits apoptosis of mouse
breast cancer JygMC(A) cells. Cancer Sci. 105:974–982. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang K, Long B, Zhou LY, Liu F, Zhou QY,
Liu CY, Fan YY and Li PF: CARL lncRNA inhibits anoxia-induced
mitochondrial fission and apoptosis in cardiomyocytes by impairing
miR-539-dependent PHB2 downregulation. Nat Commun.
5:35962014.PubMed/NCBI
|
|
35
|
Yang L, Lin C, Jin C, Yang JC, Tanasa B,
Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, et al:
lncrna-dependent mechanisms of androgen receptor-regulated gene
activation programs. Nature. 500:598–602. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang K, Liu CY, Zhou LY, Wang JX, Wang M,
Zhao B, Zhao WK, Xu SJ, Fan LH, Zhang XJ, et al: APF lncRNA
regulates autophagy and myocardial infarction by targeting
miR-188-3p. Nat Commun. 6:67792015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shi SJ, Wang LJ, Yu B, Li YH, Jin Y and
Bai XZ: LncRNA-ATB promotes trastuzumab resistance and
invasion-metastasis cascade in breast cancer. Oncotarget.
6:11652–11663. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shen X, Xie B, Ma Z, Yu W, Wang W, Xu D,
Yan X, Chen B, Yu L, Li J, et al: Identification of novel long
non-coding RNAs in triple-negative breast cancer. Oncotarget.
6:21730–21739. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen C, Li Z, Yang Y, Xiang T, Song W and
Liu S: Microarray expression profiling of dysregulated long
non-coding RNAs in triple-negative breast cancer. Cancer Biol Ther.
16:856–865. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Necsulea A, Soumillon M, Warnefors M,
Liechti A, Daish T, Zeller U, Baker JC, Grützner F and Kaessmann H:
The evolution of lncRNA repertoires and expression patterns in
tetrapods. Nature. 505:635–640. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang X, Chen Z, Mishra AK, Silva A, Ren W,
Pan Z and Wang JH: Chemotherapy-induced differential cell cycle
arrest in B cell lymphomas affects their sensitivity to Wee1
inhibition. Haematologica: Haematol. 2017:1759922017.
|
|
43
|
Hajarnis SS, Patel V, Aboudehen K,
Attanasio M, Cobo-Stark P, Pontoglio M and Igarashi P:
Transcription factor hepatocyte nuclear factor-1β (HNF-1β)
regulates MicroRNA-200 expression through a long Noncoding RNA. J
Biol Chem. 290:24793–24805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cui W, Qian Y, Zhou X, Lin Y, Jiang J,
Chen J, Zhao Z and Shen B: Discovery and characterization of long
intergenic non-coding RNAs (lincRNA) module biomarkers in prostate
cancer: An integrative analysis of RNA-Seq data. BMC Genomics. 16
Suppl 7:S32015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hu Y, Wang J, Qian J, Kong X, Tang J, Wang
Y, Chen H, Hong J, Zou W, Chen Y, et al: Long noncoding RNA GAPLINC
regulates CD44-dependent cell invasiveness and associates with poor
prognosis of gastric cancer. Cancer Res. 74:6890–6902. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wu Y, Liu H, Shi X, Yao Y, Yang W and Song
Y: The long non-coding RNA HNF1A-AS1 regulates proliferation and
metastasis in lung adenocarcinoma. Oncotarget. 6:9160–9172.
2015.PubMed/NCBI
|
